mondoBIOTECH Holding AG - Product Pipeline Review - 2013
Global Market Direct’s pharmaceuticals report, “Mondobiotech Holding AG - Product Pipeline Review - 2013” provides data on the Mondobiotech Holding AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mondobiotech Holding AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Mondobiotech Holding AG and industry-specific third party sources, put together by Global Markets Direct’s team.
- Mondobiotech Holding AG - Brief Mondobiotech Holding AG overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Mondobiotech Holding AG human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Mondobiotech Holding AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Mondobiotech Holding AG’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Mondobiotech Holding AG’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Mondobiotech Holding AG in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Mondobiotech Holding AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Mondobiotech Holding AG. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Mondobiotech Holding AG and identify potential opportunities in those areas.
Table Of Contents
mondoBIOTECH Holding AG - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 5 List of Figures 5 mondoBIOTECH Holding AG Snapshot 6 mondoBIOTECH Holding AG Overview 6 Key Information 6 Key Facts 6 mondoBIOTECH Holding AG - Research and Development Overview 7 Key Therapeutic Areas 7 mondoBIOTECH Holding AG - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 mondoBIOTECH Holding AG - Pipeline Products Glance 12 mondoBIOTECH Holding AG Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 mondoBIOTECH Holding AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 mondoBIOTECH Holding AG - Drug Profiles 16 DasKloster 0228-01 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 DasKloster-001401 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 DasKloster-003901 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 DasKloster-008001 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 DasKloster-014101 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 DasKloster-018201 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 DasKloster-021001 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 DasKloster-024701 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 DasKloster-024901 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 DasKloster-027401 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 DasKloster-050101 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 DasKloster-1000-01 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 DasKloster-1000-02 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 DasKloster-1000-04 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 DasKloster-100003 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 interferon gamma-1b 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 secretin 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 thymopentin 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 mondoBIOTECH Holding AG - Pipeline Analysis 36 mondoBIOTECH Holding AG - Pipeline Products by Therapeutic Class 36 mondoBIOTECH Holding AG - Pipeline Products by Route of Administration 38 mondoBIOTECH Holding AG - Pipeline Products By Mechanism of Action 39 mondoBIOTECH Holding AG - Recent Pipeline Updates 41 mondoBIOTECH Holding AG - Dormant Projects 42 mondoBIOTECH Holding AG - Company Statement 43 mondoBIOTECH Holding AG - Locations And Subsidiaries 45 Head Office 45 Other Locations and Subsidiaries 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables
mondoBIOTECH Holding AG, Key Information 6 mondoBIOTECH Holding AG, Key Facts 6 mondoBIOTECH Holding AG - Pipeline by Indication, 2013 9 mondoBIOTECH Holding AG - Pipeline by Stage of Development, 2013 10 mondoBIOTECH Holding AG - Monotherapy Products in Pipeline, 2013 11 mondoBIOTECH Holding AG - Phase II, 2013 12 mondoBIOTECH Holding AG - Phase I, 2013 13 mondoBIOTECH Holding AG - Preclinical, 2013 14 mondoBIOTECH Holding AG - Discovery, 2013 15 mondoBIOTECH Holding AG - Pipeline By Therapeutic Class, 2013 37 mondoBIOTECH Holding AG - Pipeline By Route of Administration, 2013 38 mondoBIOTECH Holding AG - Pipeline Products By Mechanism of Action, 2013 40 mondoBIOTECH Holding AG - Recent Pipeline Updates, 2013 41 mondoBIOTECH Holding AG - Dormant Developmental Projects,2013 42 mondoBIOTECH Holding AG, Subsidiaries 45
List of Figures
mondoBIOTECH Holding AG - Pipeline by Indication, 2013 8 mondoBIOTECH Holding AG - Pipeline by Stage of Development, 2013 10 mondoBIOTECH Holding AG - Monotherapy Products in Pipeline, 2013 11 mondoBIOTECH Holding AG - Pipeline By Therapeutic Class, 2013 36 mondoBIOTECH Holding AG - Pipeline By Route of Administration, 2013 38 mondoBIOTECH Holding AG - Pipeline Products By Mechanism of Action, 2013 39